Navigation Links
GeoVax Presents Data at AIDS Vaccine 2008 Conference
Date:10/16/2008

ATLANTA, Oct. 16 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta based, publicly traded biopharmaceutical company specializing in the prevention and treatment of infectious diseases, presented data on their AIDS vaccine (trial HVTN 065) at the AIDS Vaccine 2008 conference, on October 15 in Cape Town, South Africa. This conference comes at an exciting time for GeoVax, which is preparing to enter Phase 2 trials for its vaccine.

The presentation, titled "Two HIV DNA Primes Maximize T Cell Responses Induced by the GeoVax DNA/MVA Vaccine Regimen Administered to Healthy Seronegative Adults (HVTN 065)," was given by Dr. Paul A. Goepfert, M.D., Associate Professor, Division of Infectious Diseases, Department of Medicine, University of Alabama. Dr. Goepfert is the HVTN 065 Protocol Team chair. The trial results reveal the GeoVax DNA and MVA vaccines are safe and immunogenic (stimulate anti-HIV/AIDS immune responses) at both low (1/10th) dose and full doses. Other highlights included:

-- GeoVax vaccines were well tolerated with no or mild local and systemic reactions in the majority of trial participants.

-- 80 percent of both the low and full dose trial participants responded to the vaccine which stimulated anti-HIV T-cell (white blood cell) and antibody responses.

-- More volunteers had antibody responses to the full dose than to the 1/10th dose vaccine, whereas response rates for T cells were similar for the 1/10th and full dose.

-- Two DNA primes were more effective than one DNA prime or no DNA primes at eliciting T cell responses.

-- The 2nd MVA vaccination positively increased CD8 T cell and antibody responses.

"As the entire world tries to find a solution for the HIV/AIDS crisis, GeoVax, a front runner in the search for an effective vaccine, is on the verge of entering Phase 2 trials," said Bob McNally, CEO and President of GeoVax Labs, Inc. "The AIDS Vaccine 2008 conference is a
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update
2. U.S. Government Awards $15 Million Grant to GeoVax Labs HIV/AIDS Vaccine Program
3. GeoVax Further Strengthens Management Team
4. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
5. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
6. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
7. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
8. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
9. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
10. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
11. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... , March 3, 2015  RegeneRx Biopharmaceuticals, Inc. ... in the scientific journal, Expert Opinion on Biological ... colleague, Dr. Zhenggang Zhang , at the Henry ... reported that Thymosin beta 4 (TB4) has the capacity ... 24 hours or more post-injury, leading to neurological recovery ...
(Date:3/3/2015)... Calif. , March 3, 2015 AtheroNova Inc. ... AtheroNova Operations, Inc., filed voluntary petitions under Chapter 11 of ... District of California , Santa ... 2015. The Company,s Chapter 11 cases are expected to be ... including a Bankruptcy Court supervised asset sale process, for all ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 Genedata, ... drug discovery and life science research, today announced ... (TM) enterprise platform for use at Pfizer biopharma ... Europe. Genedata is supporting Pfizer’s global deployment and ... (GBT), Centers for Therapeutic Innovation (CTI), and Pharmaceutical ...
(Date:3/3/2015)... Mar. 03, 2015 Research and Markets ... PharmaBiotech,s new report "RNAi - Technologies, Markets and ... Because of its ability to silence any gene once ... the research tool to discriminate gene function. After the ... designed to target every gene in the genome and ...
Breaking Biology Technology:Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 2AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 3AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 4Genedata Biologics Licensed by Pfizer Inc. 2Genedata Biologics Licensed by Pfizer Inc. 3Global RNAi Market Report 2015 - Technologies, Markets and Companies 2014-2024 2Global RNAi Market Report 2015 - Technologies, Markets and Companies 2014-2024 3
... Conference Call at 10:30 a.m. ET, May 13 -, ... NTII ) today announced financial,results for its fiscal third quarter ... the three months ended March 31, 2008 were $3.7 million,compared ... Research and development expenses were $5.9 million for the ...
... DIEGO, May 12 Amylin Pharmaceuticals,Inc. (Nasdaq: AMLN ... Conference,on Wednesday, May 14, 2008 at 3:05 p.m. CT ... Vice President, Finance and Chief Financial Officer of,Amylin Pharmaceuticals, ... presentation and breakout session will be webcast, and a,recording ...
... How To Stop The Food Riots. (Atlantic and Latin ... on the,world food crisis with a primer on the ... of control, the worry is that millions more of,the ... Over the past few,months, there have been food-related riots ...
Cached Biology Technology:Neurobiological Technologies Reports Third Quarter Financial Results 2Neurobiological Technologies Reports Third Quarter Financial Results 3Neurobiological Technologies Reports Third Quarter Financial Results 4Neurobiological Technologies Reports Third Quarter Financial Results 5Newsweek International Editions: Highlights And Exclusives, May 19, 2008 2Newsweek International Editions: Highlights And Exclusives, May 19, 2008 3Newsweek International Editions: Highlights And Exclusives, May 19, 2008 4Newsweek International Editions: Highlights And Exclusives, May 19, 2008 5
(Date:2/18/2015)...  Cepheid (NASDAQ: CPHD ) today announced that ... invited investors to participate via webcast. , Cowen and ... Tuesday, March 3, 2015 at 11.20 a.m. Eastern Time ... Wednesday, March 4, 2015 at 10.25 a.m. Eastern ... webcasts for these events, please visit Cepheid,s website at ...
(Date:2/11/2015)... 11, 2015 According ... Control Market by Product (Cards and Readers, Biometrics, Controllers, ... Government, Industrial, Healthcare, Education) and By Geography - Global Forecast and ... the Access Control Market is expected to ... a CAGR of 10.6% between 2014 and ...
(Date:2/5/2015)... 5, 2015  Marken is starting its 35 th ... launched a new marketing campaign to solidify its place ... new campaign focuses on First as a ... The first headline in the series, ... with its client,s priorities. Marken recognizes the need to ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken Launches New Patient-Centric Campaign 2
... health benefits of consuming dark chocolate and cocoa mounts, ... and chocolate products deliver the most beneficial compounds, known ... production diminish the levels of cocoa flavanols. ... the effect of conventional production methods of cocoa beans ...
... Orleans, LA LSU oncologist Vince D. Cataldo, MD, ... two chemotherapy drugs now indicated for second and third-line ... remarkably effective in treating a certain subset of these ... at LSU Health Sciences Center New Orleans School of ...
... Montreal, QC March 10, 2011 In childhood, boys and ... peers. Around early adolescence, they gradually begin to include ... in Journal of Research on Adolescence suggests ... The findings show that girls tend to initiate the ...
Cached Biology News:Study clarifies the role of cocoa bean handling on flavanol levels 2Study shows new treatment strategy effective for certain lung cancers 2Early male friendship as a precursor to substance abuse in girls 2
Monoclonal antibodies conjugated with rhodamine...
... [RET-P1] to Rhodopsin Rhodopsin is a ... mammals, birds, amphibians, and reptiles. The rhodopsin ... in the retina. Immunogen: ... Specificity: This antibody specifically labels ...
... 3′-(α-Amino- p- methoxyhydrocinnamamido)-3′-deoxy-N,N-dimethyladenosine, 2HCl ... FROM MOISTURE. Protein synthesis inhibitor. Inhibits ... nascent polypeptide chains. Induces DNA fragmentation ... leukemia cells. Purity: ≥98% by ...
5X StabilCoat Immunoassay Stabilizer is a 5X concentrate solution of StabilCoat Immunoassay Stabilizer. The shelf-life of 5X StabilCoat Immunoassay Stabilizer is 2 years when stored at 4C. Product ...
Biology Products: